These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Balancing STAT Activity as a Therapeutic Strategy. Polak KL; Chernosky NM; Smigiel JM; Tamagno I; Jackson MW Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31684144 [TBL] [Abstract][Full Text] [Related]
5. Suppression of IL-2-induced T cell proliferation and phosphorylation of STAT3 and STAT5 by tumor-derived TGF beta is reversed by IL-15. Campbell JD; Cook G; Robertson SE; Fraser A; Boyd KS; Gracie JA; Franklin IM J Immunol; 2001 Jul; 167(1):553-61. PubMed ID: 11418694 [TBL] [Abstract][Full Text] [Related]
6. Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors. Iwata-Kajihara T; Sumimoto H; Kawamura N; Ueda R; Takahashi T; Mizuguchi H; Miyagishi M; Takeda K; Kawakami Y J Immunol; 2011 Jul; 187(1):27-36. PubMed ID: 21632716 [TBL] [Abstract][Full Text] [Related]
7. IL-2 activation of STAT5 enhances production of IL-10 from human cytotoxic regulatory T cells, HOZOT. Tsuji-Takayama K; Suzuki M; Yamamoto M; Harashima A; Okochi A; Otani T; Inoue T; Sugimoto A; Motoda R; Yamasaki F; Nakamura S; Kibata M Exp Hematol; 2008 Feb; 36(2):181-92. PubMed ID: 18023521 [TBL] [Abstract][Full Text] [Related]
8. Long non-coding RNA RP11-468E2.5 curtails colorectal cancer cell proliferation and stimulates apoptosis via the JAK/STAT signaling pathway by targeting STAT5 and STAT6. Jiang L; Zhao XH; Mao YL; Wang JF; Zheng HJ; You QS J Exp Clin Cancer Res; 2019 Nov; 38(1):465. PubMed ID: 31718693 [TBL] [Abstract][Full Text] [Related]
9. STAT3 and STAT5 Targeting for Simultaneous Management of Melanoma and Autoimmune Diseases. Logotheti S; Pützer BM Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31569642 [TBL] [Abstract][Full Text] [Related]
10. Role and mechanism of programmed death-ligand 1 in hypoxia-induced liver cancer immune escape. Wen Q; Han T; Wang Z; Jiang S Oncol Lett; 2020 Apr; 19(4):2595-2601. PubMed ID: 32218809 [TBL] [Abstract][Full Text] [Related]
11. Direct Targeting Options for STAT3 and STAT5 in Cancer. Orlova A; Wagner C; de Araujo ED; Bajusz D; Neubauer HA; Herling M; Gunning PT; Keserű GM; Moriggl R Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31817042 [TBL] [Abstract][Full Text] [Related]
12. Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition. Groner B; von Manstein V Mol Cell Endocrinol; 2017 Aug; 451():1-14. PubMed ID: 28576744 [TBL] [Abstract][Full Text] [Related]
13. Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution. Bharadwaj U; Kasembeli MM; Robinson P; Tweardy DJ Pharmacol Rev; 2020 Apr; 72(2):486-526. PubMed ID: 32198236 [TBL] [Abstract][Full Text] [Related]
14. NLGP counterbalances the immunosuppressive effect of tumor-associated mesenchymal stem cells to restore effector T cell functions. Ghosh T; Nandi P; Ganguly N; Guha I; Bhuniya A; Ghosh S; Sarkar A; Saha A; Dasgupta S; Baral R; Bose A Stem Cell Res Ther; 2019 Sep; 10(1):296. PubMed ID: 31547863 [TBL] [Abstract][Full Text] [Related]
15. A Jak2-selective inhibitor potently reverses the immune suppression by modulating the tumor microenvironment for cancer immunotherapy. He W; Zhu Y; Mu R; Xu J; Zhang X; Wang C; Li Q; Huang Z; Zhang J; Pan Y; Han J; Dong L Biochem Pharmacol; 2017 Dec; 145():132-146. PubMed ID: 28859967 [TBL] [Abstract][Full Text] [Related]
16. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy. Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993 [TBL] [Abstract][Full Text] [Related]
17. Active STAT5 regulates T-bet and eomesodermin expression in CD8 T cells and imprints a T-bet-dependent Tc1 program with repressed IL-6/TGF-β1 signaling. Grange M; Verdeil G; Arnoux F; Griffon A; Spicuglia S; Maurizio J; Buferne M; Schmitt-Verhulst AM; Auphan-Anezin N J Immunol; 2013 Oct; 191(7):3712-24. PubMed ID: 24006458 [TBL] [Abstract][Full Text] [Related]
18. STAT3 signaling contributes to the high effector activities of interleukin-15-derived dendritic cells. Okada S; Han S; Patel ES; Yang LJ; Chang LJ Immunol Cell Biol; 2015; 93(5):461-71. PubMed ID: 25582338 [TBL] [Abstract][Full Text] [Related]
19. IL-6 activates STAT5 in T cells. Tormo AJ; Letellier MC; Sharma M; Elson G; Crabé S; Gauchat JF Cytokine; 2012 Nov; 60(2):575-82. PubMed ID: 22854263 [TBL] [Abstract][Full Text] [Related]
20. A preferential role for STAT5, not constitutively active STAT3, in promoting survival of a human lymphoid tumor. Nagy ZS; Rui H; Stepkowski SM; Karras J; Kirken RA J Immunol; 2006 Oct; 177(8):5032-40. PubMed ID: 17015686 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]